|
Agent |
Dose | |
|
Starting |
Target | |
|
ACEIs | ||
|
Enalapril |
2.5 mg bid |
10-20 mg bid |
|
Captopril |
6.25 mg tid |
50 mg tid |
|
Lisinopril |
2.5-5 mg once daily |
20-35 mg once daily |
|
Ramipril |
2.5 mg once daily |
5 mg bid |
|
Trandolapril |
0.5 mg once daily |
4 mg once daily |
|
ARBs | ||
|
Candesartan |
4 mg or 8 mg once daily |
32 mg once daily |
|
Valsartan |
40 mg bid |
160 mg bid |
|
Losartana |
50 mg once daily |
150 mg once daily |
|
ARNI | ||
|
Valsartan/sacubitrilb |
24/26 mg bid |
97/103 mg bid |
|
Contraindications: table 3.9-3. a Losartan is mentioned in the 2012 European Society of Cardiology guidelines but it has been stressed in the text that the benefits of using the agent may be lower. b Valsartan component in the valsartan/neprilysin combination pill Entresto is more potent than valsartan monotherapy pills available on the market. Therefore, caution must be exercised not to equate valsartan dosage found in current monotherapy with the dose found in Entresto, as it will lead to prescribing a higher than the intended dose. | ||
|
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; ARNI, angiotensin receptor neprilysin inhibitor; bid, 2 times a day; tid, 3 times a day. | ||